Microcap Ledger Indaptus Therapeutics, Inc. $INDP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 133,242,324 [10-Q 2026-08-13]
What the company doesAI summary of filing
Indaptus Therapeutics is a clinical-stage biotechnology company developing systemically-administered immunotherapy candidates based on attenuated, non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immune responses against cancer and viral infections. The company's lead product candidate, Decoy20, is in clinical development; it initiated a Phase 1 trial in 2023 for advanced solid tumors and subsequently pursued a combination study with BeOne's anti-PD-1 antibody Tislelizumab, which has since been discontinued with no participants remaining and no current plans for new clinical trials. Indaptus is pre-revenue and has historically funded operations through public and private offerings of equity securities; as of the filing date, the company is evaluating strategic options for a potential acquisition or investment transaction following a December 2025 investment by David E. Lazar. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$4.34M | −$8.94M | $7.55M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$20.85M | −$14.82M | $8.51M | [DEF 14A 2026-07-16] |
| FY ended Dec 2024 | — | −$15.02M | −$12.32M | $5.79M | [DEF 14A 2026-07-16] |
- Quarterly cash burn
- −$4.47M
- Cash runway Estimate
- ~5.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 10,196,884 | [10-Q 2024-11-12] |
| 2025-03-12 | 14,429,244 | [10-K 2025-03-13] |
| 2025-05-12 | 16,034,444 | [10-Q 2025-05-14] |
| 2025-08-12 | 1,106,529 | [10-Q 2025-08-13] |
| 2025-11-11 | 1,751,163 | [10-Q 2025-11-12] |
| 2026-03-16 | 2,242,324 | [10-K 2026-03-17] |
| 2026-05-15 | 113,242,324 | [10-Q 2026-05-15] |
| 2026-08-13 | 133,242,324 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-08-17; declared effective 2026-08-25 [S-3 2026-08-17]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-31] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-01-20 | Ben-Tzvi Avraham | grant | 25,000 | — | [4 2026-01-22] |
| 2025-12-22 | Sassi Nir | grant | 26,758 | $2.03 | [4 2025-12-29] |
| 2025-12-22 | Meckler Jeffrey A | grant | 216,617 | $2.03 | [4 2025-12-29] |
| 2025-12-22 | Newman Michael James | grant | 52,204 | $2.03 | [4 2025-12-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Material agreement entered |
| 2026-09-10 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-08 | 8-K | Material agreement entered |
| 2026-09-04 | 8-K | Director or officer change |
| 2026-09-04 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-01 | 8-K | Material agreement entered |
| 2026-08-31 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-26 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-17 | S-3 | Registration statement |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations; Shareholder vote results |
| 2026-07-16 | DEF 14A | Proxy statement |
Alerts for $INDP
Email me when Indaptus Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.